
Pricing
Latest News
Latest Videos

Podcasts
More News

Germany's new health insurance law more than doubles mandatory drug rebates. Here is why it matters for US pharma pricing and launches.

Manufacturers must forecast and commercialize products across commercial, government and cash economies to maximize lifetime enterprise value.

Amber Hussain Siddique explains why that inventory economics, FEFO compliance gaps, and freight cost structures are driving America's persistent drug shortage crisis and what it takes to fix it.

A US Section 301 probe into Germany's drug pricing could bring tariffs on APIs and finished drugs, raising new supply chain and pricing risks.

In this week's Pharma Pulse, Europe’s drug pricing standoff intensifies, CMS moves to formalize Medicare negotiation rules, FDA expands OTC naloxone, and DSV launches a new pharma air route.

CMS' proposed framework for 2029 and beyond closes a potential formulation loophole and raises the stakes for launch planning.

USP's Annual Drug Shortages Report reveals a sharp rise in product discontinuations, driven by unsustainable generic pricing, upstream geographic concentration, and manufacturing complexity.

Cash pay is re-emerging as biopharma brands rethink insurance barriers, patient access, and affordability in a fragmented payer market.

The Supreme Court declined pharma appeals, letting Medicare drug price negotiations under the IRA proceed, solidifying federal pricing authority.

Jeremy Richardson explains how direct-to-patient models increase drug pricing transparency and demonstrate value.

As specialty drug costs rise, employers and sponsors must balance alternative funding programs and in-benefit optimization to achieve sustainable savings without disrupting patient care.

As cell and gene therapies move beyond ultra-rare disease indications into broader patient populations, the commercialization infrastructure built around them is due for a fundamental redesign.

Will Shrank, MD, evaluates opportunities and challenges in specialty pharma over the next few years.

At Asembia AXS26, Dee Chaudhary broke down how shifting US drug pricing policy is tightening payer controls and changing pharmaceutical pricing and forecasting.

Avalere Health analysts map the converging pressures reshaping the drug pricing and distribution landscape ahead of November.

TailorMed broadens patient support beyond copay help, adding five modules that link access, affordability and adherence across specialty medications.

Amber Hussain-Siddique says operational discipline in inventory and logistics is the vital, yet overlooked, key to sustaining low-cost generic drug supplies in the U.S.

In today’s Pharma Pulse, Eli Lilly calls for the U.K. government to overhaul its drug pricing framework and the FDA approves Ponlimsi.

New Benefit 360 and Direct Fund models aim to bridge the gap between clinical eligibility and employer-sponsored coverage.

In today's Pharma Pulse, the NCPA warns of a severe cash flow crisis for independent pharmacies under the Medicare Drug Price Negotiation Program, while Norgine commits sixty-seven million dollars to modernize its UK manufacturing hub.

A guide to how the IRA is reshaping Medicare Part D, price negotiations, manufacturer liability, and pharmacy operations, along with what it means for access, adherence, and commercial strategy.

From new formulations and vial formats to retailer expansion and pricing pressure, evolving GLP-1 strategies are transforming distribution models, reimbursement dynamics, and long-term supply planning.

In the final part of his Pharma Commerce video interview, John Stanford, Incubate’s executive director, argues that while Medicare price controls may reduce federal spending, they have yet to meaningfully improve patient access—contending that true reform must address insurance design, out-of-pocket costs, and the long-term impact on life sciences innovation and investment.

The company is significantly lowering the US list prices for its popular weight loss and diabetes GLP-1 drugs, signaling a broader shift in pricing strategy as competition intensifies and access pressures grow.

In the second part of his Pharma Commerce video interview, John Stanford, Incubate’s executive director, points out how uneven Medicare negotiation timelines between small molecules and biologics are influencing R&D and venture funding decisions, according to biotech investors advocating for legislative changes.















